Tesamorelin: A Defined GHRH Analogue With Established Human Research

Tesamorelin is structurally defined

Tesamorelin is based on the GHRH sequence with a modification that improves resistance to enzymatic degradation. It activates the pituitary GHRH receptor and increases endogenous growth-hormone release and downstream IGF-1.

The human evidence is indication specific

Controlled trials supported an FDA-approved prescription product for reduction of excess abdominal fat in adults with HIV and lipodystrophy. That is a narrow regulatory conclusion tied to defined populations, endpoints, manufacturing, and labeling.

Approved labeling documents important risks

The approved product carries information concerning elevated IGF-1, glucose intolerance, fluid retention, hypersensitivity, injection-site reactions, malignancy-related contraindications, and disruption of the hypothalamic-pituitary axis.

Evidence should not be generalized

An approved indication does not validate unrelated claims about general body composition, performance, aging, or recovery. Nor does it establish the quality of a material sold outside the approved supply chain.

Product-level status must be explicit

A research material bearing the name tesamorelin is not the FDA-approved finished drug. Equivalence would require evidence concerning identity, content, impurities, formulation, stability, and manufacturing controls.

This article is provided for scientific and educational purposes. It does not describe or recommend human or veterinary use. Research findings may be limited by study design, model selection, material identity, sample size, or lack of independent replication.